Investigational New Drugs : Impact Factor & More
eISSN: 1573-0646pISSN: 0167-6997
Share this on:
Key Metrics
CiteScore 
6.2
Eigenfactor
0.005 - 0.01
H-Index
94
Impact Factor
< 5
SJR
Q1Oncology
SNIP
0.85
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Investigational New Drugs
Investigational New Drugs Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1983 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Investigational New Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Investigational New Drugs
Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence.
- 23 Jul 2026
- Investigational new drugs
The novel agent VP79s synergistically enhances venetoclax activity in multiple myeloma cells.
- 17 Jul 2026
- Investigational new drugs
Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database.
- 10 Jul 2026
- Investigational new drugs
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.
- 7 Jul 2026
- Investigational new drugs
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.
- 22 Jun 2026
- Investigational new drugs
Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database.
- 19 Jun 2026
- Investigational new drugs
Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence.
- 23 Jul 2026
- Investigational new drugs
The novel agent VP79s synergistically enhances venetoclax activity in multiple myeloma cells.
- 17 Jul 2026
- Investigational new drugs
Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database.
- 10 Jul 2026
- Investigational new drugs
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.
- 7 Jul 2026
- Investigational new drugs
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.
- 22 Jun 2026
- Investigational new drugs
Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database.
- 19 Jun 2026
- Investigational new drugs
FAQs on Investigational New Drugs
How long has Investigational New Drugs been actively publishing? 
What is the publishing frequency of Investigational New Drugs?
How many articles did Investigational New Drugs publish last year?
What is the eISSN & pISSN for Investigational New Drugs?
What is Citescore for Investigational New Drugs?
What is the H Index for Investigational New Drugs ?
What is SNIP score for Investigational New Drugs?
What is the SJR for Investigational New Drugs?
Who is the publisher of Investigational New Drugs?
